218 related articles for article (PubMed ID: 28032931)
1. FKBP51 regulates cell motility and invasion via RhoA signaling.
Takaoka M; Ito S; Miki Y; Nakanishi A
Cancer Sci; 2017 Mar; 108(3):380-389. PubMed ID: 28032931
[TBL] [Abstract][Full Text] [Related]
2. Formin-like2 regulates Rho/ROCK pathway to promote actin assembly and cell invasion of colorectal cancer.
Zeng Y; Xie H; Qiao Y; Wang J; Zhu X; He G; Li Y; Ren X; Wang F; Liang L; Ding Y
Cancer Sci; 2015 Oct; 106(10):1385-93. PubMed ID: 26258642
[TBL] [Abstract][Full Text] [Related]
3. DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion.
Tripathi V; Popescu NC; Zimonjic DB
Oncogene; 2014 Feb; 33(6):724-33. PubMed ID: 23376848
[TBL] [Abstract][Full Text] [Related]
4. Flavone inhibits migration through DLC1/RhoA pathway by decreasing ROS generation in breast cancer cells.
Zhu W; Ma L; Yang B; Zheng Z; Chai R; Liu T; Liu Z; Song T; Li F; Li G
In Vitro Cell Dev Biol Anim; 2016 May; 52(5):589-97. PubMed ID: 26935193
[TBL] [Abstract][Full Text] [Related]
5. α-TEA inhibits the growth and motility of human colon cancer cells via targeting RhoA/ROCK signaling.
Yao J; Gao P; Xu Y; Li Z
Mol Med Rep; 2016 Sep; 14(3):2534-40. PubMed ID: 27432222
[TBL] [Abstract][Full Text] [Related]
6. The RhoA GTPase-activating protein DLC2 modulates RhoA activity and hyperalgesia to noxious thermal and inflammatory stimuli.
Chan FK; Chung SS; Ng IO; Chung SK
Neurosignals; 2012; 20(2):112-26. PubMed ID: 22204965
[TBL] [Abstract][Full Text] [Related]
7. Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma.
Wong CC; Wong CM; Ko FC; Chan LK; Ching YP; Yam JW; Ng IO
PLoS One; 2008 Jul; 3(7):e2779. PubMed ID: 18648664
[TBL] [Abstract][Full Text] [Related]
8. A phosphorylation switch controls the spatiotemporal activation of Rho GTPases in directional cell migration.
Cao X; Kaneko T; Li JS; Liu AD; Voss C; Li SS
Nat Commun; 2015 Jul; 6():7721. PubMed ID: 26166433
[TBL] [Abstract][Full Text] [Related]
9. SHROOM2 inhibits tumor metastasis through RhoA-ROCK pathway-dependent and -independent mechanisms in nasopharyngeal carcinoma.
Yuan J; Chen L; Xiao J; Qi XK; Zhang J; Li X; Wang Z; Lian YF; Xiang T; Zhang Y; Chen MY; Bei JX; Zeng YX; Feng L
Cell Death Dis; 2019 Jan; 10(2):58. PubMed ID: 30683844
[TBL] [Abstract][Full Text] [Related]
10. FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential.
Romano S; Staibano S; Greco A; Brunetti A; Nappo G; Ilardi G; Martinelli R; Sorrentino A; Di Pace A; Mascolo M; Bisogni R; Scalvenzi M; Alfano B; Romano MF
Cell Death Dis; 2013 Apr; 4(4):e578. PubMed ID: 23559012
[TBL] [Abstract][Full Text] [Related]
11. DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA.
Joshi R; Qin L; Cao X; Zhong S; Voss C; Min W; Li SSC
J Biol Chem; 2020 Jan; 295(2):645-656. PubMed ID: 31806702
[TBL] [Abstract][Full Text] [Related]
12. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity.
Leung TH; Ching YP; Yam JW; Wong CM; Yau TO; Jin DY; Ng IO
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15207-12. PubMed ID: 16217026
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-induced ARHGAP26 deficiency inhibits the proliferation and migration of human ductus arteriosus smooth muscle cell through activating RhoA-ROCK-PTEN pathway.
Li M; Ye L; Ye X; Wang S; Zhang H; Liu J; Hong H
J Cell Biochem; 2019 Jun; 120(6):10106-10117. PubMed ID: 30592323
[TBL] [Abstract][Full Text] [Related]
14. The Na+-H+ exchanger-1 induces cytoskeletal changes involving reciprocal RhoA and Rac1 signaling, resulting in motility and invasion in MDA-MB-435 cells.
Paradiso A; Cardone RA; Bellizzi A; Bagorda A; Guerra L; Tommasino M; Casavola V; Reshkin SJ
Breast Cancer Res; 2004; 6(6):R616-28. PubMed ID: 15535843
[TBL] [Abstract][Full Text] [Related]
15. Increased diacylglycerol kinase ζ expression in human metastatic colon cancer cells augments Rho GTPase activity and contributes to enhanced invasion.
Cai K; Mulatz K; Ard R; Nguyen T; Gee SH
BMC Cancer; 2014 Mar; 14():208. PubMed ID: 24646293
[TBL] [Abstract][Full Text] [Related]
16. O-GlcNAcylation promotes migration and invasion in human ovarian cancer cells via the RhoA/ROCK/MLC pathway.
Niu Y; Xia Y; Wang J; Shi X
Mol Med Rep; 2017 Apr; 15(4):2083-2089. PubMed ID: 28259907
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration.
Heering J; Erlmann P; Olayioye MA
Exp Cell Res; 2009 Sep; 315(15):2505-14. PubMed ID: 19482022
[TBL] [Abstract][Full Text] [Related]
18. The tumor suppressor protein DLC1 maintains protein kinase D activity and Golgi secretory function.
Jensch A; Frey Y; Bitschar K; Weber P; Schmid S; Hausser A; Olayioye MA; Radde NE
J Biol Chem; 2018 Sep; 293(37):14407-14416. PubMed ID: 30045871
[TBL] [Abstract][Full Text] [Related]
19. SEPT9_i1 regulates human breast cancer cell motility through cytoskeletal and RhoA/FAK signaling pathway regulation.
Zeng Y; Cao Y; Liu L; Zhao J; Zhang T; Xiao L; Jia M; Tian Q; Yu H; Chen S; Cai Y
Cell Death Dis; 2019 Sep; 10(10):720. PubMed ID: 31558699
[TBL] [Abstract][Full Text] [Related]
20. Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway.
Holeiter G; Heering J; Erlmann P; Schmid S; Jähne R; Olayioye MA
Cancer Res; 2008 Nov; 68(21):8743-51. PubMed ID: 18974116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
